What Pontalon Treats: Main Uses and Benefits

Pontalon (Mefenamic Acid) provides targeted, symptomatic support across several key clinical domains characterized by acute discomfort, inflammation, and fever. This medication is applied in clinical settings that involve acute or disruptive symptom patterns.

---

Key Therapeutic Focus

Pontalon is commonly used to help with the easing of mild to moderate pain, addressing conditions like primary dysmenorrhea (menstrual cramps), soft tissue injuries, and post-procedural discomfort following dental or minor surgical interventions. It is applied when symptoms create noticeable physiological strain, offering supportive relief when symptoms interfere with routine activities.

A key application is the management of symptoms associated with primary dysmenorrhea. In addition to easing pain, the medication is applied in settings marked by temporary physiological imbalance where symptom clusters may become intense or disruptive, such as the co-occurrence of pain, swelling, and elevated body temperature. This action contributes to easing the overall symptom load.

---

“Applied across domains where additional symptomatic support is needed, Pontalon assists with maintaining functional stability when these episodic symptoms interfere with daily comfort.”

---

Quick Fact: Relief for Episodic Pain and Cramping

Who Can and Cannot Use Pontalon?

Pontalon (Mefenamic Acid) use is strictly governed by population eligibility rules established in official regulatory documents. The medicine is contraindicated and must not be used by specific groups.

Absolute Contraindications

Use is contraindicated for individuals with known hypersensitivity to Mefenamic Acid or who experience allergic reactions after taking aspirin or other NSAIDs. Absolute prohibitions also apply to patients with active gastrointestinal (GI) ulceration or chronic inflammation of the GI tract, including inflammatory bowel disease, and those with a history of recurrent GI bleeding. Furthermore, use is forbidden in patients with severe heart, kidney, or liver failure, and is contraindicated during the last trimester of pregnancy and for pain after Coronary Artery Bypass Graft (CABG) surgery.

Age-Specific and Conditional Rules

Safety and efficacy have not been established for children younger than 14 years of age, and use is generally not recommended in this group. For older adults, the medicine should be used with caution and close monitoring due to an increased risk of serious adverse reactions. Eligibility is conditional upon pre-existing status: patients with impaired renal or hepatic function require careful consideration, and temporary conditions such as dehydration or hypovolemia must be corrected before administration.

Interactions with other medicines and products

The official regulatory profile for Pontalon (Mefenamic Acid) details several clinically significant interactions, primarily categorized by additive toxicity risk or altered drug exposure.

Contraindications and Administration Restrictions

Co-administration with other systemic Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, is formally contraindicated due to the significantly increased risk of gastrointestinal ulceration and bleeding. The medication is also strictly contraindicated for the management of peri-operative pain associated with coronary artery bypass graft (CABG) surgery.

Documented Pharmacological Interactions

Interacting Class/Substance	Official Interaction Outcome
Oral Anticoagulants (e.g., Warfarin)	Enhanced effects, leading to a substantial increase in bleeding risk.
Lithium and Methotrexate	Reduced renal clearance, resulting in elevated plasma concentrations and increased risk of toxicity.
Antihypertensives (e.g., ACE Inhibitors, AIIA)	Reduction in the blood pressure-lowering effect.
Antacids (containing Magnesium Hydroxide)	Increase the rate and extent of Mefenamic Acid absorption.
Alcohol	Increased risk of gastrointestinal bleeding and ulceration.

Timing and Population Notes

A specific timing rule dictates that Mefenamic Acid must not be taken for 8-12 days after mifepristone administration to avoid reducing the effects of mifepristone. Furthermore, the increased risk of nephrotoxicity when combined with ACE inhibitors or AIIA is noted as being especially significant in elderly patients.

Inhibition of Prostaglandin Synthesis

The mechanism of Mefenamic Acid is rooted in its primary pharmacodynamic action: the reversible, non-selective inhibition of the Cyclooxygenase (COX) enzyme system, which includes both the constitutive COX-1 and inducible COX-2 isoforms. By blocking the catalytic site of these enzymes, the compound suppresses the conversion of arachidonic acid into prostaglandins and other eicosanoids, which function as crucial local chemical mediators. This molecular intervention modifies the entire downstream physiological signaling cascade.

---

Dual Modulation of Physiological Signaling

The systemic consequence of reduced prostaglandin biosynthesis affects the peripheral nervous system and the central thermoregulatory center. Peripherally, the diminished availability of Prostaglandin E2 (PGE2) prevents the sensitization of nociceptors (pain-sensing neurons), thereby modifying the pain signaling pathway. Centrally, the inhibition of PGE2 production in the hypothalamus supports a return to the thermal set point. This dual action facilitates specific modulations of the physiological responses driven by eicosanoid activity.

Pontalon (Mefenamic Acid) is formulated for oral administration in dosage forms that typically include 250 mg capsules and 500 mg tablets. The general usage protocol requires the drug to be taken with food, milk, or a full glass of water to ensure proper intake and absorption conditions.

Administration guidelines emphasize utilizing the lowest effective dose for the shortest duration necessary to manage symptoms, a principle established in pharmaceutical documentation. Adult dosing regimens vary by country. In the United States, acute pain relief typically begins with a 500 mg initial dose, followed by 250 mg every six hours as needed. This regimen is generally not to exceed seven days for acute pain.

When the medication is used for primary dysmenorrhea, administration should commence at the onset of bleeding and associated symptoms, and the total duration is usually restricted to two or three days per menstrual cycle.

High-level population rules specify that older adults should adhere strictly to the lowest effective dosage for the shortest time possible. Product labeling indicates administration for patients 14 years of age and older. If a scheduled dose is missed, instructions advise skipping the forgotten dose and resuming the regular schedule, rather than attempting to take two doses together.

Research evidence / Overview of studies for Pontalon

The evidence base for Pontalon (Mefenamic Acid) is composed of findings from official regulatory sources, including Randomized Controlled Trials (RCTs) and systematic reviews. The research has been evaluated in addressing short-term, acute symptom patterns within its studied indications. The following overview describes what researchers have studied, the types of outcomes they measured, and where the limitations or uncertainties remain.

---

Evidence for Primary Dysmenorrhea (Menstrual Cramps)

The clinical evaluation in the research context of primary dysmenorrhea, where studies evaluate physical discomfort, has been primarily addressed through short-term RCTs and clinical summaries. Researchers examined outcomes related to physical discomfort, primarily by using standardized assessment scales to measure pain intensity and documenting the requirement for additional pain-relieving medication over the study period. Research so far indicates that the evidence is primarily structured around the acute symptom phase, and long-term health outcomes were not the subject of these measurements.

Evidence for Acute Mild to Moderate Pain

For the research related to general acute discomfort, the evidence includes single-dose and short-term course RCTs. The outcomes monitored were measurements of acute pain axes, such as Pain Intensity Difference (PID) scores, and changes in the use of rescue analgesic medication. The primary limitation here is that follow-up durations are limited. The research emphasizes single-dose observation and short-course use.

Evidence for the Antipyretic (Fever Reduction) Property

The research exploring the antipyretic (fever reduction) properties was mostly derived from clinical pharmacology studies and the established profile of the drug's class. Studies examined outcomes related to physiological strain or stress, specifically measuring changes in body temperature over the hours following administration. This finding is often derived from the general evidence of this class of medicines.

---

What Remains Uncertain in the Research Landscape

Official scientific reviews highlight several areas where certainty remains low or research gaps exist:

• Long-Term Context: Long-term effects are not fully established, and there is limited information on outcomes beyond the acute treatment phase.
• Subgroup Findings: Data for certain groups, particularly very young adolescents and the elderly, remain insufficient within the clinical evaluation studies. These results apply only to the populations studied in the primary research.

Common questions about Pontalon (FAQ)

Q: What is Pontalon?

A: Pontalon is a brand name for the drug mefenamic acid, which belongs to a class of medicines known as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). It is primarily used for the short-term relief of pain and inflammation.

Q: What conditions is Pontalon prescribed to address?

A: Pontalon (mefenamic acid) is approved for the short-term relief of mild to moderate acute pain in adults and adolescents aged 14 and older. It is also approved for the treatment of primary dysmenorrhea (menstrual pain).

Q: Is Pontalon available over-the-counter?

A: In many regions, Pontalon (mefenamic acid) is typically available only with a prescription from a healthcare provider. Its availability without a prescription may vary based on local regulations.

Q: What should I discuss with my healthcare provider before taking Pontalon?

A: Before starting treatment with Pontalon, it is important to discuss your full medical history with your healthcare provider, particularly if you have:

• A history of stomach ulcers or bleeding in the stomach or intestines.
• Heart disease, a history of heart attack or stroke, or are planning to have Coronary Artery Bypass Graft (CABG) surgery.
• High blood pressure (hypertension).
• Kidney or liver disease.
• Asthma.
• Are pregnant, planning to become pregnant, or breastfeeding.

Q: What are the possible side effects associated with Pontalon?

A: Like all medicines, Pontalon may be associated with potential side effects. The most commonly reported side effects may include:

• Stomach upset, such as nausea, vomiting, or diarrhea.
• Heartburn or indigestion.
• Dizziness or drowsiness.

Serious warnings are associated with the use of NSAIDs like mefenamic acid, including the potential for an increased risk of serious gastrointestinal issues (such as bleeding or ulcers) and cardiovascular risks (such as heart attack or stroke), particularly with higher doses or prolonged use. You should seek immediate medical attention if you experience symptoms like chest pain, trouble breathing, or signs of internal bleeding.

Q: How does Pontalon work in the body?

A: Pontalon (mefenamic acid) is an NSAID. It is understood to exert its effects by interfering with the action of certain natural substances in the body. This action is thought to contribute to the reduction of pain and inflammation associated with its approved uses.

How to Store and Dispose of Pontalon (Mefenamic Acid)

The storage and handling of Pontalon (Mefenamic Acid) must strictly adhere to the conditions documented in government-approved labeling.

Storage Conditions

Pontalon must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be kept tightly closed in its original container to protect it from moisture and should be protected from light. It is mandatory to keep Pontalon out of the sight and reach of children and to keep it from freezing.

Disposal Instructions

Unused or expired Pontalon should be disposed of using a drug take-back program. If a program is unavailable, follow the guidance to mix the medicine with an unappealing substance, place the mixture in a sealed container, and discard it in the household trash. It must not be flushed down a toilet or poured down a drain.